13:05 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Dicerna's DCR-PHXC reduces urinary oxalate levels in Phase I

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight...
19:06 , Sep 7, 2018 |  BC Extra  |  Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.79 (14%) to $14.81 on Friday after raising $100 million via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and...
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together, data...
19:51 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Alexion's long-acting C5 inhibitor meets in Phase III switch trial

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on April 26 that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302...
19:19 , Apr 26, 2018 |  BC Extra  |  Clinical News

Alexion gains on long-acting C5 inhibitor data, guidance

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on Thursday that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302 trial...
23:19 , Apr 20, 2018 |  BC Extra  |  Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing. In...
17:58 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Apellis reports additional Phase Ib data for C3 inhibitor in PNH

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported data from eight evaluable patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received Soliris eculizumab in the open-label, New Zealand Phase Ib PADDOCK trial showing that once-daily 270...
16:41 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Phase I/II of Roche PNH candidate temporarily halted

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said enrollment was temporarily stopped in the international Phase I/II COMPOSER trial evaluating RG6107 (SKY59) in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) after two patients who received...
16:38 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Alexion's long-acting C5 inhibitor meets in Phase III

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said that ALXN1210, its long-acting formulation of Soliris eculizumab, met the co-primary and four key secondary endpoints in the Phase III ALXN1210-PNH-301 trial to treat paroxysmal nocturnal hemoglobinuria (PNH). The company...
23:53 , Mar 15, 2018 |  BC Extra  |  Clinical News

Alexion's long-acting C5 inhibitor meets in Phase III

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said Thursday that ALXN1210, its long-acting formulation of Soliris eculizumab, met the co-primary and four key secondary endpoints in the Phase III ALXN1210-PNH-301 trial to treat paroxysmal nocturnal hemoglobinuria (PNH). The...